Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00948922 · OUTCOME

Molecular Complete Response (CR) Rates in Patients With Multiple Myeloma

Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma · Source last updated 2019-09-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
End of 2 year, post transplant follow-up

What was measured

Complete Response according to International Myeloma Working Group uniform response criteria. CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in bone marrow.

Analysis population: Patients were in very good partial response at the time on enrollment without sufficient plasma cells in bone marrow to be able to perform assay for molecular response.

Groups in this outcome

A: Allogeneic Stem Cell Transplant

Allogeneic Stem Cell Transplant: Fludarabine+Melphalan+Bortezomib followed by Allogeneic Rescue.

B: Autologous Stem Cell Transplant

Autologous Stem Cell Transplant: Melphalan+Bortezomib followed by Autologous Rescue.

BE: Group B Expansion

Group B Expansion on Bortezomib Maintenance: Autologous Only.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
A: Allogeneic Stem Cell Transplant0
B: Autologous Stem Cell Transplant0
BE: Group B Expansion0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    2. group Id
      OG001
      value
      0
    3. group Id
      OG002
      value
      0
    units
    Participants
description
Complete Response according to International Myeloma Working Group uniform response criteria. CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in bone marrow.
groups
  1. description
    Allogeneic Stem Cell Transplant: Fludarabine+Melphalan+Bortezomib followed by Allogeneic Rescue.
    id
    OG000
    title
    A: Allogeneic Stem Cell Transplant
  2. description
    Autologous Stem Cell Transplant: Melphalan+Bortezomib followed by Autologous Rescue.
    id
    OG001
    title
    B: Autologous Stem Cell Transplant
  3. description
    Group B Expansion on Bortezomib Maintenance: Autologous Only.
    id
    OG002
    title
    BE: Group B Expansion
population Description
Patients were in very good partial response at the time on enrollment without sufficient plasma cells in bone marrow to be able to perform assay for molecular response.
reporting Status
POSTED
time Frame
End of 2 year, post transplant follow-up
title
Molecular Complete Response (CR) Rates in Patients With Multiple Myeloma
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice